LGND as reported
Ligand Pharmaceuticals Incorporated reported $291M of revenue over the trailing twelve months, +55% on the year before. 11 reported series are charted on this page, each one as filed.
$291M
Revenue, trailing twelve months · to Q2 2026 · +55% against the twelve months before
- Net Income
- $197M
Net Income · −360% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $131M
Free Cash Flow · +145% year on year · trailing twelve months to Q2 2026
- Op Margin
- 29%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $291M | +55% | Q2 2026 |
| Net Income | $197M | −360% | Q2 2026 |
| EPS | $9.41 | −333% | Q2 2026 |
| Gross Margin | 91% | n/a | Q3 2019 · 27 quarters behind |
| Op Margin | 29% | n/a | Q2 2026 |
| Net Margin | 57% | n/a | Q2 2026 |
| ROE | 13% | n/a | Q2 2026 |
| ROA | 7.6% | n/a | Q2 2026 |
| ROIC | −0.51% | n/a | Q1 2015 · 45 quarters behind |
| Free Cash Flow | $131M | +145% | Q2 2026 |
| P/E | 30.6 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Ligand Pharmaceuticals Incorporated (LGND) - Revenue & ProfitRevenue & ProfitLigand Pharmaceuticals Incorporated (LGND)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com